Thyroid cancer affects between 10 000 and 15 000 people per year in the US. Typically, this disease can be controlled with surgical resection and radioiodide treatment. However, resistance to these conventional therapies is observed in some patients, who develop intractable anaplastic thyroid cancer (ATC), for which no effective therapies exist. Recently, a sizable fraction of undifferentiated or poorly differentiated thyroid cancers were shown to contain mutations in b-catenin, an oncogenic protein involved in the etiology of cancers of many tissues. We developed a conditionally replicative adenovirus (named 'HILMI') which, by virtue of TCF response elements drives E1A and E1B expression, replicates specifically in cells with an active Wnt/b-catenin pathway. We show that several thyroid cancer cell lines, derived from undifferentiated or anaplastic tissues and possessing an active Wnt/b-catenin pathway, are susceptible to cell killing by HILMI. Furthermore, viral replication in ATC cells as xenograft tumors in nude mice was observed, and prolonged survival of mice with ATC tumors was observed following administration of the HILMI therapeutic vector. The results warrant further development of this therapeutic approach for ATC patients.
Introduction
Currently, anaplastic thyroid cancer (ATC) is a clinically unmanageable diagnosis, with patient mortality rates of 80-90% within one year of diagnosis and average life expectancy of less than 6 months. [1] [2] [3] ATC comprises only 1-2% of all thyroid cancer cases in the USA, but accounts for 30-50% of the thyroid cancer-related deaths. 4, 5 Traditional treatments, like radiation and chemotherapy (alone or in combination) have been used to treat ATC, but the disease does not appear to be responsive to these treatment approaches. 6, 7 Thus, novel therapies for ATC are clearly needed.
One such approach is gene therapy. Recently, a promising gene therapy application based on conditionally replicative adenoviruses (CRAd) has been developed. Primary methods of CRAd design include deletion of genes not essential to viral replication in cancer cells but essential to replication in normal cells [8] [9] [10] [11] and the use of tissue or tumor specific promoters (TSPs) to drive expression of genes required for viral life cycle, including E1a and E1b. [12] [13] [14] CRAd developed from both categories have shown promise in multiple pre-clinical and clinical studies. 15, 16 Wnt signaling has recently emerged as a critical pathway in carcinogenesis. 17 The most intensely studied target of the Wnt pathway is b-catenin, an oncogenic protein activated in most colon cancers 17 and a multitude of other neoplasms. [18] [19] [20] The canonical Wnt pathway centers on a cytoplasmic complex composed of APC, GSK3b, and Axin. Phosphorylation of b-catenin by this complex leads to recognition by the E3 ubiquitin ligase b-TrCP, ubiquitination and subsequent degradation of b-catenin. By using this elaborate phosphorylation and ubiquitination system, an intact Wnt pathway maintains low levels of b-catenin. 21, 22 However, in a wide variety of cancers, hyperactivation of the Wnt pathway, by specific mutations or DNA methylation of APC, Axin, or mutations in the ubiquitination region of b-catenin, [23] [24] [25] [26] results in loss of proteasomal turnover of b-catenin and subsequent nuclear translocation and accumulation of b-catenin, where it co-activates the T-cell factor/ lymphocyte enhancer factor (TCF/LEF) family of transcription factors as well as many nuclear receptors. 24, 25 b-Catenin/TCF transactivation upregulates multiple target genes, many of which are involved in cell cycle progression, invasion, motility and differentiation [27] [28] [29] [30] [31] and thus cancer progression. Lastly, b-catenin plays a role in normal cellular physiology by anchoring cadherins to the cytoskeleton for homotypic cell-cell adhesion., 32 Based on a recent finding that the Wnt/b-catenin pathway is hyperactive in poorly differentiated and undifferentiated thyroid cancer tissues [33] [34] [35] we designed a TSP driving replication of the E1 region. Initially, we confirmed that b-catenin hyperactivity is present in multiple thyroid cancer cell lines, including those isolated from patients with undifferentiated or poorly differentiated cancers. In order to exploit b-catenin hyperactivity in late stage thyroid cancers, we created an adenovirus (named HILMI) containing a synthetic promoter with four TCF response elements driving both E1A and E1B expression. Replication and cytopathic effects (CPE) of HILMI approaches that of wild-type adenovirus serotype 5 (WTAd5) in thyroid cancer cell lines as well as in a colon cancer cell line containing an active Wnt pathway. Little replication or CPE was observed in cells without an active Wnt pathway. We further tested the HILMI construct in nude mice harboring xenografts from the ARO thyroid cancer cell line. HILMI treatment delayed ARO tumor growth and significantly lengthened survival compared to ARO tumors treated with non-replicative virus. Based on these results, we suggest that development of this therapeutic approach for ATC patients is warranted.
Materials and methods

Materials
ARO, NPA and WRO cells were a generous gift of Guy F Juillard (University of California at Los Angeles). ML-1 cells were kindly provided by Daniela Grimm (University of Regensburg, Germany). KTC1 cells were a generous gift of Junichi Kurebayashi (Kawasaki Medical School, Japan). CAL62, BHT101, TT2609CO2, 8305C and 8505C cells were purchased from the DSMZ (Braunschweig, Germany). Cell lines are described in Table 1 . OT-FLASH and OF-FLASH were kindly provided by Bert Vogelstein (Johns Hopkins University). p1020E1 and pAd288 were provided by Xavier Danthinne (OD260 Inc., Boise, ID, USA).
Isolation of nuclei
Cells (1 to 5 Â 10 7 ) were pelleted in ice-cold PBS, then resuspended in cold Buffer A (20 mM HEPES, 0.5 mM. MgCl 2 , 0.5 mM DTT, 5 mM KCl, 2 mM CaCl 2 , protease inhibitors) and incubated for 15 min. Cells were then pelleted, resuspended in Buffer A-S (Buffer A with 0.25 M sucrose), dounced in a Dounce homogenizer using the tight pestel, and then pelleted again. Crude nuclei were washed and pelleted four times with Buffer A þ 0.5% NP-40, then frozen at À801C until use.
Western blot analysis
Fifty micrograms of protein were loaded into a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and separated at 150 V for 2-2.5 h and transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were blotted with mouse anti-bcatenin antibody (Calbiochem, San Diego, CA, 1:1000) or rabbit anti-b-tubulin (Santa Cruz, Santa Cruz, CA, 1:500). Bands were visualized with anti-mouse or antirabbit antibodies conjugated to HRP and the West Pico Chemiluminescent HRP Kit (Pierce, Rockford, IL).
Immunohistochemistry
Cells were grown on poly-L-lysine coated coverslips overnight then fixed in 4% formaldehyde in PBS for 30 min at 371C. Anti-b-catenin or mouse pre-immune serum (Santa-Cruz) was incubated in dilution solution (1:1000) followed by Texas Red labeled anti-mouse secondary antibody. Hoechst was used to stain DNA. Slides were stored at À201C until use. Immunostaining was visualized with a Nikon E800 epifluorescent microscope using MetaMorph software.
Luciferase assays
Transfection conditions for each cell line were optimized with TFX-20 (Promega, Madison, WI), according to the manufacturer's instructions. Cells were plated in 12-well dishes 24 h before transfection. To determine b-catenin activity, cells were transfected with OT-FLASH or OF-FLASH. Empty vector or SV40-luciferase vector was utilized as negative and positive controls, respectively. OT-FLASH contains two TCF response elements upstream from a minimal promoter and luciferase; OF-FLASH contains two mutated TCF response elements upstream of a minimal promoter and luciferase. At 24 h after transfection, cells were lysed, sonicated for 1 s, and assayed for luciferase activity using the Luciferase assay System (Promega). b-Catenin activity was determined by dividing the OT-FLASH value by the OF-FLASH value. Values 41 indicate b-catenin activity. 
Adenovirus construction
A synthetic promoter was created containing four TCF response elements (TCFRE). A synthetic promoter was designed by annealing to strands of sequence 5 0 P-GATCCGATCAAAGGACTTGATCAAAGGTGGTCC TTTGATCG CATCCTTTGATCG-3 0 OH and 5 0 P-TCGA CGATCAAAGGATGCGATCAAAGGA CCACCTTTG ATCAAGTCCTTTGATCG-3 0 OH. The TCFRE are in bold. Sequences were designed to contain BamHI and SalI overhangs. The annealed sequence was ligated to BamHI/ SalI digested p1020E1, which contains the adenoviral E1a and E1b genes. The resultant plasmid (pTCFRE-1020E1) was then linearized with PacI (NEB). Linearized pTCFRE-1020E1 was co-transfected with pAd288 (contains the right end of the Ad5 genome) into PERC6 cells in six-well dishes. PERC6 transfectants were freeze/thawed, and the lysate was used to infect progressively larger populations of cells. The virus was then purified on CsCl gradient, dialyzed against PBS and frozen at À801C. Wild-type recombination was not detected with polymerase chain reaction (PCR)-based assays (data not shown).
Cytopathic effects assays
Cells (5000 cells/well) were seeded into 96-well dishes. The next day, cells were infected with either non-replicative adenovirus (Ad-luc), HILMI, or WTAd5. Six wells for each cell line were left as uninfected controls. After 1 week, CPE was visualized by staining with crystal violet/ methanol. Wells were washed to remove excess crystal violet, then cells were lysed in 1% SDS and agitated overnight before the OD 600 of each well was measured. The percentage of cells surviving for each dose was calculated by dividing the average OD 600 for the treatment by the OD 600 of untreated cells. The IC 50 of each virus was estimated by creating a linear regression between the data points immediately above and below 50% survival.
TaqMan assay
To determine genome quantity, 100 ml of supernatant from each well was proteolyzed, phenol-chloroform extracted, and precipitated with sodium acetate/ethanol. DNA was resuspended in 200 ml H 2 O and 2 ml was assayed using TaqMan 
Xenografts
All animal studies were approved by the Indiana University School of Medicine Animal Care and Use Committee. ARO cells were injected into the right flank (10 6 cells per injection) of 7-week-old athymic nude mice (n ¼ 60; Harlan, Indianapolis IN). To calculate tumor volume, calipers were used to measure tumors as an ellipsoid in two dimensions (lw 2 p/6, where w is the smaller dimension and l is the larger dimension). Approximately 2-3 weeks later, tumors were injected with 10 9 PFU of either HILMI or Ad-GFP. Tumor volume was measured once to twice a week throughout the study. On days 3 and 7 post-injection, two animals from each group were killed for tumor resection. The tumors were divided into two approximately equal pieces. One half was fixed in 10% formalin and sectioned for staining, and the other was frozen at À801C. Kapla--Meier curves were created and analyzed using Prism 3.0.
Statistical analysis
Quantitative variables, such as b-catenin activitity measured by luciferase expression, CPE measured under different virus concentration, and mouse tumor size, were analyzed with a two-sample t-test. Both mean and s.e. are reported. Time to event outcome, such as survival time, is analyzed by a log-rank test. The Kaplan-Meier curve is presented. All Po5% are considered statistically significant.
Results
b-Catenin activity in thyroid cancer cell lines
We first performed TCFRE dependent luciferase expression assays to determine b-catenin activity in the cell lines (Figure 1a ). Luciferase activity in KTC1 and TT2609CO2 transfected with SV40-luciferase was not detectable; therefore, TCFRE-based reporter data for these two cell lines was not available (data not shown). ARO and BHT101 cells showed definitive b-catenin/TCF dependent reporter activity (Po0.05); weak but statistically significant b-catenin activity was seen in 8305C and CAL62 cell lines (Po0.02). Transfection efficiency for 8505C was very low (data not shown), so it is possible that the activity might be enhanced or statistically significant using other methods of monitoring reporter activity in this cell line.
The reporter gene activity findings were confirmed using two additional approaches. Immunocytochemistry was used to determine the cellular localization of bcatenin in the cell lines (Figure 1b) . Nuclear staining of bcatenin was observed in ARO and BHT101 cells, but not in cell lines lacking reporter activity. Interestingly, little membranous staining was observed, but intense cytoplasmic staining was seen in 8505C, 8303C and CAL62 cells. This finding is consistent with other recent reports of cytoplasmic staining observed in the majority of thyroid cancers. 35 The presence of cytoplasmic b-catenin also correlates with target gene expression, indicating that there may be b-catenin-independent mechanism(s) for activating TCF response elements. 35 Nuclear isolates of selected thyroid cancer cell lines were also tested for the presence of b-catenin (Figure 1c) . In ARO and NPA cells, b-catenin was found in the nuclear fraction, and no b-catenin was found in cell lines lacking reporter activity (although KTC1 reporter activity could not be ascertained due to poor transfection efficiency). Purity of the nuclear extracts was confirmed by blotting with b-tubulin, which is located primarily in the cytoplasm. The presence of b-catenin in the nuclei of NPA cells by this assay may reflect the increased sensitivity of immunoblot analysis compared to immunocytochemical methods. In total, these studies confirm high b-catenin-dependent transcriptional activity in ARO and BHT101 cells, as well as the presence of some activity and disrupted subcellular localization in other cell lines.
Although we were unable to assess Wnt pathway activity in normal human thyrocytes, two previous studies show strong evidence that it is indeed inactive. Both Rao et al. 36 and Garcia-Rostan et al. 34 show that b-catenin is localized to the membrane of thyrocytes in cultured thyrocytes an sections through normal thyroid, respectively.
Construction of a conditionally replicative adenovirus
We utilized the p1020E1 vector, which is constructed to transcribe E1A and E1B genes in opposite directions from a central promoter (Figure 2a) . We then created a synthetic promoter with four TCFREs, with two of the response elements oriented to activate transcription from the right of the promoter, and two TCFREs driving transcriptional activation from the left of the promoter. The shuttle vector pTCFRE-p1020E1 was then cotransfected with pAd288, containing the rest of the adenoviral genome to generate the adenovirus (referred to as HILMI herein). To confirm that the correct construct was propagated, two PCR products were amplified: one specific to the construct and the other specific for wild-type recombination (data not shown; primer sequences available on request).
HILMI-induced CPE in thyroid cancer cell lines
In order to test the activity of HILMI on thyroid cancer cell lines, we measured the CPE of different concentrations of the virus. Thyroid cancer cell lines were infected with MOI ¼ 1000 Ad-luc, HILMI or WTAd5 and then serially diluted. After 1 week, supernatants were harvested for genome copy quantification, and the dishes were analyzed for CPE. Staining revealed extensive CPE in (b) Cells were stained with mouse anti-bC and Texas Red-labeled goat anti-mouse. DNA was stained with Hoechst (blue). Mislocalization was observed in all cell lines tested, but nuclear staining was only observed in ARO, BHT101 and SW480 cells. (c) Whole cell (W) and nuclear (N) extracts were blotted for the presence of bC (top) and b-tubulin (bT) (bottom). ARO showed high levels of nuclear; less nuclear bC was observed in NPA cells. As expected, staining for bT, a cytoplasmic marker, was not observed in nuclear extracts.
Wnt/b-catenin pathway-based adenovirus therapy P H Abbosh et al several cell lines, which we categorize as harboring active b-catenin (Figure 1) , indicating that the cell lines with a hyperactive Wnt/b-catenin pathway supported replication of HILMI (Figure 2b) . We quantitated the amount of CPE compared to the positive and negative control viruses as described in Methods (Figure 2c ). Using this quantitative assay, we determined that 8505C and CAL62 cells were permissive to HILMI replication to the same extent as WTAd5. The IC 50 s for HILMI and WTAd5 were identical in these cell lines. Furthermore, ARO, SW480 and 8305C cells permitted HILMI replication, but not quite to the same extent as WTAd5. When supernatants were quantitatively analyzed for amounts of Ad5 genome, cell lines that supported HILMI replication (BHT-101, SW480; Figure 3a and b) released 10-100 times more virions compared to TT2609-CO2 (Po0.0005 TT2609-CO2 vs BHT-101; Figure 3c ). Compared to AdLuc although, HILMI replicated in SW480, BHT-101 and TT-2609-CO2 (Po0.0005). HILMI replication-competent BHT101 and SW480 cells shed amounts of virus comparable to cells infected with WTAd5 at several MOI doses, while TT2609-CO2 cells shed significantly less HILMI virus than WTAd5 infected cells. We carried these studies out in another non-permissive cell line (NPA) and another permissive cell line (ARO) and found similar patterns of quantitative replication. These data confirm that HILMI replication-induced cell death is markedly increased thyroid cancer cell displaying hyperactive Wnt/ b-catenin pathway.
HILMI delays the growth of ARO xenografts
To determine whether HILMI therapy is applicable in vivo, ARO xenografts in nude mice were utilized. Animals were divided into two groups based on tumor size: one with tumors between 50 and 100 mm 3 in volume, and the other with 100-150 mm 3 in volume. Animals with large or small tumors were then further subdivided and treated with either HILMI or AdGFP as a negative control. All tumors were injected with 10 9 PFU of either therapeutic vector. Mice were killed when tumors grew to 400 mm 3 or when mice showed signs of morbidity. To monitor for signs of adenoviral replication, two tumors from each Wnt/b-catenin pathway-based adenovirus therapy P H Abbosh et al group were harvested on days 3 and 7 post-injection. In HILMI-injected tumors, hematoxylin and eosin staining showed multiple foci of cells displaying pyknosis, nuclear blebbing and eosinophilic cytoplasm, indicative of viral replication and cell death (Figure 4a and b) . In contrast, no cells in AdGFP-injected tumors showed signs of viral replication (Figure 4c ). Tumor sections were also stained for late adenovirus proteins. Staining for late adenovirus proteins was widespread in tumors from 3 and 7 day HILMI-injected tumors, but low or undetectable in Ad-GFP-injected tumors (Figure 4d and e) . Some sections showed pyknosis in areas of adenovirus protein staining. The finding of these phenomena concurrently is highly suggestive that adenovirus replication caused the observed cell death. Profound tumor growth was observed in all AdGFPinjected mice, and tumors in these mice reached 400 mm To analyze survival after each treatment, KaplanMeier curves were generated (Figure 5a and b) . Mice treated with HILMI survived significantly longer than mice treated with AdGFP (Po0.0001 for small tumors, Po0.01 for large tumors). Complete, sustained responses were observed only in small tumor, HILMI-injected mice (20% of the mice in this group showed sustained complete responses; Figure 5a ). All mice with sustained responses survived 44 months. Collectively, these results confirm that HILMI has in vivo as well as in vitro activity.
Discussion
In the present study, we show that the Wnt/b-catenin pathway is active in thyroid cancer cell lines derived from poorly differentiated or anaplastic thyroid cancer. To utilize Wnt pathway hyperactivity in thyroid cancer as a basis for therapeutic interventions, we developed a synthetic promoter containing only TCF/b-catenin response elements and placed it upstream of the adenoviral E1A and E1B TATA-boxes. This conditionally replicative adenovirus, HILMI, only replicates and kills cells with a hyperactive Wnt/b-catenin pathway. Furthermore, Wnt/b-catenin pathway-based adenovirus therapy P H Abbosh et al treatment with HILMI resulted in significant inhibition of tumor growth and, in some animals, long-term tumor growth suppression. The use of the thyroglobulin promoter for conditional expression of therapeutic genes or conditional replication has been shown to be effective in cells which express this marker, [37] [38] [39] [40] [41] however, undifferentiated thyroid cancers often have reduced or absent thyroglobulin. To our knowledge, this is the first report to use transcriptionally driven replication specifically for undifferentiated thyroid cancer.
CRAd systems have recently been developed to treat thyroid cancer in pre-clinical models, 37, 42 similar to the approach taken in the present study. ONYX-015, which lacks functional E1B 55K, replicates specifically in tumors. Although this phenotype was originally thought to be due to loss of p53 activity in cancer, recent findings have shown that the phenotype is caused by complemention the mRNA export function of E1B 55K 43 in cancer cells. The other recently described vector uses the thyroglobulin promoter to drive E1A expression, 37 which replicates specifically in thyroglobulin expressing cells and therefore may be more effective in differentiated cancers.
Although b-catenin is frequently mutated in thyroid cancer tissue specimens, 33, 34 no mutations in APC or CTNNB1 (the gene encoding b-catenin) have been previously reported in many of the cell lines used in this study. It appears that an alternative mechanism(s) of b-catenin activation exists, as we have recently discussed. 44 In addition, markers of b-catenin activity, such as nuclear localization and TCF/b-catenin-dependent reporter activity, were increased in the thyroid cancer cell lines. Interestingly, while all of the cell lines showed cytoplasmic and/or nuclear staining, none displayed strictly membranous b-catenin staining. The level of staining was consistent with a lower level of TCF/b-catenin-dependent reporter activity (compared to SW480, a colon cancer cell line with abundant b-catenin in the nucleus and cytoplasm and B100-fold increased transactivational activity compared to ARO cells). While a cell line with mutant CTNNB1 may display stronger transactivational activity, mutations in CTNNB1 have not been described for the cell lines used in this study. A cell line with higher b-catenin activity due to an exon 3 mutation may result in higher HILMI activity.
Placement of TCF/b-catenin response elements upstream of adenoviral E1A and E1B TATA-boxes resulted in a conditionally replicative adenovirus that only replicated in and killed cells with a hyperactive Wnt/ b-catenin pathway. Analysis of CPE showed that replication of the virus occurred only in cells containing an Wnt/b-catenin pathway-based adenovirus therapy P H Abbosh et al active Wnt/b-catenin pathway. Additionally, the level of CPE produced by HILMI and WTAd5 were similar in several of the cancer cell lines that permitted HILMI replication, indicating that maximal or near maximal damage was achieved. It is important to note, however, that even though 8305C and 8505C cells had minimal transcriptional reporter activity, HILMI replicated to near WTAd5 levels. This may be due to an artifact from low transfection efficiency in the reporter assay. We also showed, using quantitative PCR analyses to quantitate actual genome copy numbers, that prolific genome replication occurred only in cells permissive to HILMI, further confirming the specificity of this construct.
Using nude mouse xenograft models of human thyroid cancer, we showed that treatment with HILMI significantly inhibited tumor growth and caused long-term tumor eradication in some animals. It is puzzling why only one-fifth of the mice with small tumors treated with HILMI showed long-term remissions (even though most had a slightly reduced tumor size at 3 days). A possible explanation is that after injection of HILMI, small tumors (50-100 mm 3 ) exhibited a more robust response than large tumors (4100 mm 3 ). After injection of an oncolytic virus, tumor size can be thought of as a function of the rates of continuous tumor growth and tumor eradication by the virus. ARO tumors appeared to grow very quickly in this study, so the rate of growth may have outstripped the rate of oncolysis in the larger tumors. Furthermore, less virus may have been present at day 7 than at day 3 and as time post-injection increased, tumor growth would most likely exceed oncolysis. The possibility of an effect of needle path differences through these relatively small tumors (B5 mm diameter) cannot be overlooked. Tumor heterogeneity within the treatment group, in terms of tumor growth or microenvironment, may have been a contributing factor, but this seems unlikely, given the uniformity of growth in the control groups.
There are several potential ways to enhance the response to HILMI treatment, aside from our choice of cell line model. If the primary reason for treatment failure is related to tumor growth surpassing viral replication, then combining oncolysis with another modality may increase the chance of a complete response. In support of this hypothesis, combining external radiation with ONYX-015 greatly enhanced the response of anaplastic thyroid cancer xenograft tumors. 45 Furthermore, clinical head and neck cancer studies showed that conventional radiotherapy or chemotherapies greatly increased the response to ONYX-015. 15 To enhance viral spread throughout the tumor, it may be possible to increase transductional efficiency. Previous studies have shown that alterations to the viral knob can greatly increase the transductional efficiency of adenovirus. 46, 47 Although HILMI efficiently killed ARO cells in culture, 0.8 MOI is still required, and it may not be possible to achieve this level of MOI in a tumor. However, if lower amounts of virus can achieve comparable amounts of CPE, then this modification may serve as a means to enhance tumor response. Indeed, the insertion of the RGD motif to the HI loop of adenoviral knob increased transductional efficiency up to five-fold at an MOI of 1 (Abbosh and Nephew, unpublished observations).
In conclusion, we show that poorly differentiated or undifferentiated/anaplastic thyroid cancer cell lines frequently display Wnt/b-catenin hyperactivity. By targeting this pathway with CRAd, pathway specific cell killing was achieved using in vitro systems and xenograft tumors. Although the mechanism of pathway hyperactivation does not appear to be due to CTNNB1 mutation, other mechanisms clearly exist that can lead to the same phenomenon. Future studies should include exploration of such alternate mechanisms, as well as the development of strategies to enhance Wnt/b-catenin-dependent oncolysis, including combination therapies or re-engineering the virus. Wnt/b-catenin pathway-based adenovirus therapy P H Abbosh et al following agencies for supporting this work: Thyroid Research and Advisory Council (TRAC)/Abbott Laboratories (Grant SYN-1201-07) and National Cancer Institute grant R01 CA-85289. This work is dedicated to Hilmi Abbosh who passed away during the preparation of this manuscript due to anaplastic thyroid cancer.
